Consumers are surrounded by food that is highly conducive to weight gain. No one likes dieting and very few have lasting success. But now weight-loss injections are seen as gamechangers, yielding results that seem miraculous for people who have struggled with their weight.
Around the world, obesity, high blood pressure, and abnormal blood sugar and lipid levels (so-called “metabolic syndrome”) have now been shown to affect 31% of women and 26% of men. The same study estimated that globally 1.54 billion adults had metabolic syndrome in 2023.
The new genre of weight loss injections (GLP-1 agonists) have been shown to reduce weight by 16-23% in roughly one year. These drugs are expensive, but some healthcare programmes cover the cost for those who need them the most.
In the UK, they are covered by the NHS for patients who are both severely obese and also suffer from specific weight-related health problems such as cardiovascular disease and type 2 diabetes. Some who can afford to pay may be able to get a prescription with less-pressing health conditions.
In the meantime, prices of the drugs are starting to come down thanks to commercial competition and patents expiring. And a more convenient pill form is now available in the US and likely to become available in some other markets in the near future, meaning the overall uptake of these drugs could grow exponentially.
This might all seem like bad news for the food industry. After all, the people who are taking these drugs, often for at least a year, have significantly reduced appetite. This will amount to a sizeable drop in demand for food products. So it’s interesting to consider how the food industry might react to this – with an aggressive response that revamps food product lines to promote better nutrition and health? Or with a wait-and-see approach to determine the long-term future of the drugs?
